The aging process is characterized by a high level of complexity with a progressive decline in several physiological systems coexisting with multiple chronic diseases (comorbidity), presence of cognitive and functional impairment and geriatric syndromes. Use of multiple drugs and problems in nutritional status are relevant components of this complex spectrum. Nutritional status may influence the pharmacokinetic and pharmacodynamic of many drugs, conversely drugs can impair nutrition by causing adverse drug reactions such as nausea and loss of appetite. The present article describes potential interactions between nutritional status and drug use in the elderly. The role of nutritional status in the pharmacokinetic of drugs (including absorption, distribution, metabolism and elimination) is reviewed and most relevant food drugs interactions are assessed.
Changes occurring in advanced age can impact on nutritional status, including modifications in secretion and action of hormones that regulate appetite, changes in gastrointestinal motility, taste loss and functional decline of multiple systems, including organs that directly affect drug disposition.
Several publications have shown that pharmacokinetic of drugs (including absorption, distribution, metabolism and elimination) may be modified by nutritional status, determining therapeutic or toxic response [1] .
Drug absorption can be impaired by different factors commonly observed in the elderly: decreased intestinal blood flow, altered gastrointestinal motility, increased gastric pH [2] , diminished gastrointestinal absorption. For example, absorption of drugs normally soluble at low pH (i.e. ketoconazole, itraconazole and dipyridamole), could be reduced when gastric pH increases [3] .
Also drug distribution might be influenced by nutritional changes occurring in advanced age. Aging is characterized by changes in body composition, characterized by gain of fat mass and loss of lean mass. These changes lead to reduction of drug's volume of distribution and might result in changes in drug concentration. Metabolism of many drugs might be impaired by physiological changes observed during aging, including decreased intestinal blood flow, reduced perfusion of the liver and kidneys. Particularly, a reduction in hepatic blood flow might result in a decrease in hepatic cleareance of drugs with a high hepatic extraction ratio (labetalol, levodopa, propranolol, verapamil) [4] . Presystemic cleareance, also known as first pass effect, occurring primarily in the intestine and in the liver, is often reduced and drugs bioavailability is impaired. Phase I function (oxidation, reduction and hydrolysis) is predominantly reduced in advanced age, while phase II (conjugation) does not appear to be markedly modified. These alterations are enhanced by reduction in cytocrome P450 isoenzymes activity. Guengerich [5] investigated the CYP450 content in liver biopsy sample in 226 people and found that CYP content declines at rate of approximately 0.07 nmol/g of liver after 40 years of age.
Concerning drug elimination, renal function progressively decreases with increasing age and latent renal insufficiency is a relevant problem in the elderly. The lack of correlation between lean body weight and muscle mass may determine overestimation of creatinine clearance. In addition, dehydration or diuretic therapy, common concerns among older adults, may precipitate acute renal insufficiency leading to 
Food-Drug Interactions
Nutrients and drugs might share the same receptors for absorption, metabolism and excretion. Elderly patient are particularly at risk of food-drug interactions because of the elevated number of drugs used. It has been estimated that more than 30% of all prescribed drugs are taken by this population [6] .
Food drug interactions are defined as alteration of pharmacokinetics or pharmacodynamics of a drug or nutritional element, or a problem in nutritional status as a consequence of the use of a drug (Table 1) . It results in a reduction or an increment in bioavailability of a drug which may lead to greater risk of treatment failure or increased toxicities, respectively. Four types of drug-nutrient interactions are known.
Type I -Direct interaction of food and drugs
It refers to interactions between drug and nutritional element through biochemical (hydrolysis, oxidation) or physical reactions. These are common when drugs and nutritional formulation are co-administered intravenously or by enteral feeding and result in a reduction in the amount of drug or nutrient absorbed. Several recommendations exist to minimize type I drug-nutrient interactions: preformulated oral solution or suspensions are preferred instead of crushing tablets when administering drugs through enteral feeding tubes, drugs should not be mixed directly with feeding enteral or parenteral formulas and tubes should be flushed with water before and after drug administration.
Type II -Interactions with absorption
The presence of food in the stomach and proximal intestine may reduce drug absorption through delayed gastric emptying, competition for binding sites with nutrients, chelating of drug by food cations. In addition, meals rich in fat, stimulating the release of bile salts, increase the dispersion of highly lipophilic drugs. Concomitant release of cholecystokinin slows gastro-intestinal motility and increases the contact time between drug and intestine wall. It is well known that to optimize absorption, certain drugs should be taken with food while other drugs between meals. For example, blood concentration of tetracycline can be reduced by over 50% if consumed with milk and dairy products because it is chelated by calcium.
Type III -Interaction with distribution
These interactions occur when drugs and nutritional element entered the systemic circulation. They are related to changes of cellular or tissue distribution or transport. For example, fat soluble drugs may have a longer half life as a consequence of an increment in fat mass because of a slower release from fatty tissues.
Type IV -Interaction with excretion
These interactions involve drug/nutrient clearance and elimination modulated by enterohepatic and/or renal metabolism. An example of this type of interactions is represented by CYP450 drug metabolizing enzymes and some nutrients. Grapefruit juice is a selective intestinal CYP 3A4 inhibitor and the overall concentration of some drugs can be increased by more than fivefold when taken with grapefruits. Drugs that undergo extensive first-pass effect are similarly involved in these kinds of interactions: propranolol, metoprolol can have an increased bioavailability after a high protein meal owing to enhanced hepatic blood flow [7] whereas methyldopa can have a decreased bioavailability when ingested with a protein-rich meal [8] .
In addition, some dietary protein can interact with medications ( Table 2 ). For example, MAO-I drug class can interact with the amino acid tyramine that is contained in aged cheese, fermented food and red wines. Tyramine is an indirect sympathomimetic amine that releases norepinephrine from the adrenergic neurons, causing a significant pressor response. Tyramine is metabolized by the enzyme monoamine oxidase before any significant increases in blood pressure. If the activity of the enzyme is reduced by MAO-I drugs, severe and potentially fatal increment in blood pressure can occur. Finally, Vitamin K-rich foods (broccoli, green leafy vegetables) can alter response to anticoagulant agents as warfarin. When ingested in high amounts they could be associated with anticoagulants failure with consequent need for higher dose. Similarly, an increased risk of bleeding is observed when elderly who have been stable on warfarin suddenly decrease their intake of this vitamin k-rich food.
Polypharmacy, Adverse Drugs Reactions and Nutritional Status
Older adults show the co-occurrence of multiple chronic diseases (comorbidity) and conditions that cannot be ascribed to a specific organ
Food-Drug Interactions Drug-Nutrient Interactions
Changes in lean body mass total body fluids and plasma protein concentrations Compromised nutritional status due to chronic disease Impairing in gastrointestinal, hepatic e/o renal function On prolonged polypharmacy
Drugs that need to be taken for prolonged periods Drugs with a narrow therapeutic windows (warfarin, digoxin) Drugs that require dietary restriction or regulation (warfarin and vit k rich food)
Drugs associated with impaired gastric motility Drugs associated with anorexia, nausea, vomiting or taste alterations According to a recent study, more than 10% of older adults living in the community receive ≥ 10 drugs and this rate rises among institutionalized elderly [9] . Although the evidence of benefits, including prevention or control of disease and symptom relief, is compelling, there is also evidence that in the elderly a greater consumption of medications contributes to decreased medication adherence [10] , increased risk of adverse drug events [11] and it is strongly associated with decline in nutritional status, functional ability and cognitive capacity [12] .
Drug treatment and polypharmacy may worsen nutritional status, most commonly as a manifestation of adverse drug effects [12] [13] [14] . Several studies have shown an inverse association between the number of drugs and nutritional status [15] [16] [17] . In particular, a recent crosssectional study performed among community-dwelling elderly aged 65 or older found a significant reduction in the intake of fiber, several fat -soluble vitamins (A,D, E) and water-soluble vitamins (B1, B3 and B7) and an increased intake of glucose, sodium, and dietary cholesterol with increasing number of drugs used.
In the elderly, drugs most likely to have nutritional implication are those with a narrow therapeutic window (i.e. Warfarin, Clozapine, Digoxin), those with sharp dose-concentration profile (i.e. MTX, Phenytoin) or those requiring an high plasma concentration (i.e. Cordarone or antibiotics). However, drugs taken for prolonged periods (such as those used to treat chronic conditions or those requiring specific rules in term of the timing of food intake, dietary restrictions or regulation) are at high risk for nutritional problems and drug-nutrient interaction.
In addition, drugs can reduce food intake through a variety of mechanisms. Several drugs may affect appetite by either central or peripheral effects, inducing sedation or evoking adverse response when food is ingested [18] . Centrally acting mechanisms include catecholaminergic or dopaminergic (L-dopa) modulators which act to suppress appetite. Peripherally acting mechanisms lead to a reduction of appetite directly by inhibition of gastric emptying (L-Dopa) or indirectly by causing nausea and diarrhea (Table 3) , xerostomia, ageusia (Table 4 ) or olfactory disturbances [19] . Interestingly, a recent study performed in hospitalized older adults [20] showed that advanced age (>75years) and polypharmacy were positively and independently related to an increased risk of reduced sour taste perception. Indeed, several drugs have been associated clinically with taste complaints such as "loss of taste" (ACE inhibitors, Cephalosporins, Clopidogrel, Metformin), "bitter taste" (aspirin, L dopa, carbamazepine) or "metallic taste" (allopurinol, captopril, nifedipine).
Nutritional implications of polypharmacy can be also mediated by a drug-induced malabsorption of nutrient such as vitamins or fluid and electrolytes imbalance (Table 2 ). For instance, chronic corticosteroid use can determine a net negative calcium balance and decrease bone mineral density owing to suppression of intestinal absorption of calcium or increment in renal calcium and phosphate excretion [21] . Metabolic effects of a long treatment with corticosteroids include also impaired glucose tolerance, gastric damage, increased protein catabolism and reduced protein synthesis with consequent reduction of muscle's mass, factor already involved in physiological modification age related and elderly frailty. Proton pump inhibitors (PPIs) are widely used in older people to treat acid peptic disorders and to reduce risk of gastrointestinal (GI) bleeding related to the use of non-steroidal anti-inflammatory drugs (NSAIDs) and low-dose aspirin. Noticeably, only 38.6% of PPI prescribing was appropriate according to National Institute for Clincal Excellence (NICE) recommendations and long term therapy was shown to be associated with several risks. Chronic PPI use seems to affect iron [22] , magnesium [23] [24] [25] [22] . Several studies [26] confirm the relationship between the use of PPIs and prevalence of diarrhea caused by alteration in gastric and intestinal wall. Treatment with PPIs induces a clinical state similar to atrophic gastritis with markedly reduced gastric acid production and pepsin activity because of high gastric pH. This condition is frequently associated with bacterial overgrowth [27, 28] which may result in malabsorption of fat, carbohydrate, protein, micronutrients and clinical manifestations of abdominal pain, diarrhea, and even malnutrition [29] .
Conclusion
The aging process is characterized by a high level of complexity which makes the care of the elderly a challenging task. A progressive decline in several physiological systems coexists with multiple chronic diseases (comorbidity), presence of cognitive and functional impairment and several geriatric syndromes. Polypharmacy and problems in nutritional status are relevant components of this complex spectrum. Limiting drug prescriptions to essential medications and periodic revaluations of drug regimens are essential to minimize drug-nutrient interactions, ultimately leading to improvement in nutritional status [30] . Similarly, evaluation of nutritional status is a key step to improve quality of prescribing: it is crucial to identify nutritional problems which can be related to drug use and assessment of nutritional factors which may influence drug efficacy. 
